Flare Therapeutics

Flare Therapeutics

  • Founded: 2021
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Advanced urothelial cancer, solid tumors
  • Drug types: ONC
  • Lead product: FX-909
  • Product link: https://www.flaretx.com/pipeline/
  • Funding: $123M B Mar 2023; $82M A May 2021
  • Investors: Pfizer Ventures, GordonMD Global Investments, Boxer Capital, Eventide Asset Management, Third Rock Ventures, Novartis, Eli Lilly



job board

Short description:

Therapeutics Targeting Transcription Factors

Drug notes:

5 additional undisclosed programs RD oncology

Long description:

Flare Therapeutics is targeting transcription factors to identify therapeutics for cancer treatment. Transcription factors (TFs) bind DNA and control gene expression, which dictates the functional output of a cell. Due to their importance, mutations in TFs are common causes of cancer, yet this protein class has remained elusive for drug discovery. Flare is changing this by designing small molecules that target the switch site of TFs to regain transcriptional control. Switch sites reflect the cooperative nature of TF domains and offer a new druggable pocket to control activity. With this information, Flare is developing a differentiated pipeline of drug programs to target the central genetic drivers of cancer and other diseases.


Flare Therapeutics
Director/ Senior Director, Scientific Computing & ...
Cambridge, MAHybrid|12 days ago
Flare Therapeutics
Scientist I/II, Mass Spectrometry and Proteomics
Cambridge, MAOn-site|29 days ago
Flare Therapeutics
Associate Director/ Director, Computational Biolog...
Cambridge, MAHybrid|43 days ago
Flare Therapeutics
Senior / Executive Medical Director
Cambridge, MA|100+ days ago
Flare Therapeutics
Don't see an opening for you? Apply anyways!
Cambridge, MA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com